Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
The 3rd International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS & iwMPN) took place on 27–29 June 2025, in Lisbon, Portugal. At this event, the world’s leading clinical researchers in MDS & MPNs shared their perspectives on how to place the evolving understanding of these hematological malignancies in a clinical context to optimize clinical care.
The iwMDS and MPN 2025 Workshop was supported by Agios, Faron, Genentech, Geron, Sumitomo Pharma, Bristol Myers Squibb, GSK and Kartos Therapeutics. Supporters have no influence over the production of content.
iwMPN 2025
The 3rd International Workshop on MDS & MPNs
27–29 June 2025 | Lisbon, Portugal
The 3rd International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS & iwMPN) took place on 27–29 June 2025, in Lisbon, Portugal. At this event, the world’s leading clinical researchers in MDS & MPNs shared their perspectives on how to place the evolving understanding of these hematological malignancies in a clinical context to optimize clinical care.
The iwMDS and MPN 2025 Workshop was supported by Agios, Faron, Genentech, Geron, Sumitomo Pharma, Bristol Myers Squibb, GSK and Kartos Therapeutics. Supporters have no influence over the production of content.
Explore roundtable discussions & interviews
View all videos
Challenging and uncommon scenarios in MPN (part I)
Young patients
Marta Sobas Wroclaw Medical University, Wrocław, Poland
Pregnancy in MPN
Susan Robinson Guy's and St Thomas' NHS Foundation Trust , London, United Kingdom
Skin cancer
Jon Lambert UCL Cancer Institute, London, United Kingdom
Challenging and uncommon scenarios in MPN (part II)
Transplantation for rare MPN
Nicola Polverelli IRCCS Policlinico San Matteo Foundation, Pavia , Italy
Novel approaches to upfront management of MF (part I)
Classification and risk stratification
Alessandro Vannucchi University of Florence, Florence, Italy
Relevance of cytopenias in MF for therapeutic decisions
Lucia Masarova The University of Texas MD Anderson Cancer Center, Houston, TX, United States
When should a low-risk patient be treated and with what?
Prithviraj Bose The University of Texas MD Anderson Cancer Center, Houston, TX, United States
What is a suboptimal responder?
Donal McLornan University College Hospital, London, United Kingdom
Novel approaches to upfront management of MF (part II)
Selinexor
Claire Harrison Guy’s and St. Thomas’ NHS Foundation Trust, London, United Kingdom
Updates on JAK inhibitors & JAKi-naïve studies
Prithviraj Bose The University of Texas MD Anderson Cancer Center, Houston, TX, United States
INCB057643 in Myelofibrosis & Myeloid Neoplasms
Adam Mead University of Oxford, Oxford, United Kingdom
Navtemadlin
Haifa Kathrin Al-Ali Martin Luther University of Halle-Wittenberg, Halle, Germany
Updates on new therapies (part I)
Interferon
Jan Bewersdorf Yale Cancer Center, New Haven, CT, United States
Imetelstat
Alessandro Vannucchi University of Florence, Florence, Italy
Nuvisertib
Firas El Chaer University of Virginia, Charlottesville, VA, United States
Elritercept
Claire Harrison Guy’s and St. Thomas’ NHS Foundation Trust, London, United Kingdom
Tagraxofusp in MF
Abdulraheem Yacoub University of Kansas Medical Center, Kansas City, KS, United States
Updates on new therapies (part II)
Updates with hepicidin targets in PV
Marina Kremyanskaya Icahn School of Medicine at Mount Sinai, New York City, NY, United States
Targeting inflammation – lessons from MDS
Shahram Kordasti King’s College London, London, United Kingdom
Novel thoughts on blastic phase and transplantation
Diagnosis and risk stratification of AP and BP
Adam Mead University of Oxford, Oxford, United Kingdom
Options for management of accelerated and blast phase: should they be treated in the same way and how should we incorporate BMT?
Donal McLornan University College Hospital, London, United Kingdom
Transplant for MF
Juan Carlos Hernández-Boluda University Hospital, Valencia, Spain
